NCT01483742 - A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions

Hepatitis C, Chronic

Interventions

DRUG

RO5024048

1000 mg orally bid, 24 weeks

DRUG

danoprevir

100 mg orally bid, 24 weeks

DRUG

peginterferon alfa-2a [Pegasys]

180 mcg weekly, 24 weeks

DRUG

ribavirin

1000-1200 mg/kg/day orally in two divided doses, 24 weeks

DRUG

ritonavir

100 mg orally bid, 24 weeks

Trial Locations (27)

1142

Auckland

3065

Fitzroy

3124

Melbourne

8140

Christchurch

10021

New York

30308

Atlanta

30309

Atlanta

32720

DeLand

32803

Orlando

33136

Miami

34094

Montpellier

35294

Birmingham

70112

New Orleans

78215

San Antonio

90807

Long Beach

92037

La Jolla

92118

Coronado

92801

Anaheim

48202-2689

Detroit

08844

Hillsborough

V6Z 2C7

Vancouver

M5G 2C4

Toronto

41-500

Chorzów

41-400

Mysłowice

02-507

Warsaw

51-149

Wroclaw

833 05

Bratislava

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY